Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
A10BK01
|
| gptkbp:brand |
gptkb:dapagliflozin
gptkb:Farxiga |
| gptkbp:chemicalFormula |
C21H25ClO6
|
| gptkbp:contraindication |
type 1 diabetes
severe renal impairment |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
Forxiga
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:Japan gptkb:United_States |
| gptkbp:mechanismOfAction |
SGLT2 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
urinary tract infection
dehydration genital infection |
| gptkbp:usedFor |
gptkb:type_2_diabetes
heart failure chronic kidney disease |
| gptkbp:bfsParent |
gptkb:Farxiga
|
| gptkbp:bfsLayer |
6
|